ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Efficacy and safety of romiplostim N01 for refractory aplastic anemia: a retrospective single-center study].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Romiplostim N01 (QL0911) is a novel thrombopoietin receptor agonist (TPO-RA) ; however, clinical data regarding its efficacy and safety in patients with refractory aplastic anemia (AA) who have failed multiple prior lines of therapy are limited. This retrospective single center study analyzed the clinical outcomes of 32 patients with refractory AA who received romiplostim N01 at Peking Union Medical College Hospital between May 2024 and December 2024. All patients had previously failed to respond to full dose cyclosporine and at least two oral TPO-RA administered for adequate treatment durations and had been treated with romiplostim N01 for ≥3 months and followed for ≥6 months. The median age of the cohort was 62 years (range, 24-79 years) , and 11 patients (34.4% ) were male. Thirty patients had transfusion-dependent non-severe AA (TD-NSAA) , and 2 had severe AA (SAA) . The median duration of romiplostim N01 treatment was 5 months (range, 3-10 months) , and the median follow-up time was 6 months (range, 6-10 months) . The overall response rates (ORR) at 3 months, 6 months, and the last follow-up were 71.9% , 75.0% , and 75.0% , respectively, and the complete response rates (CRR) were 28.1% , 28.1% , and 31.2% , respectively. The median time to hematologic response was 1 month (range, 1-4 months) , and the median time to complete response was 3 months (range, 1-4 months) , indicating a rapid onset of action even in this refractory population. A total of 14 patients (43.8% ) experienced adverse events, all of which were grade 1 and improved with symptomatic management; no dose reductions or treatment discontinuations were required, and no treatment related liver dysfunction, thrombotic events, or deaths were observed. During follow-up, relapse occurred in 3 patients who had previously responded (3/26, 11.5% ) , and newly detected myelodysplastic syndrome (MDS) -related gene mutations were identified in 2 patients (6.3% ) . No new or expanding paroxysmal nocturnal hemoglobinuria (PNH) clones were detected. These findings suggest that romiplostim N01 can induce rapid and high hematologic response rates with a favorable safety profile in patients with refractory AA who have failed full-dose cyclosporine A and multiple oral TPO-RA; no obvious short-term signals of clonal evolution were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.